Hualan Biological Engineering Inc.
002007
Pozycja w akcjach
#4390
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Cena akcji
$1.92
Kapitalizacja rynkowa
$3.50B
Zmiana (1 dzień)
-1.39%
Zmiana (1 rok)
-19.45%
Kraj
CN
Handel Hualan Biological Engineering Inc. (002007)
Kategoria
Healthcare
Zyski dla Hualan Biological Engineering Inc. (002007)
Zyski w Jun 2026 TTM: $155.12M
Według najnowszych raportów finansowych Hualan Biological Engineering Inc., obecny zysk firmy wynosi $155.12M. W roku 2024 firma osiągnęła zysk w wysokości $183.39M, spadek w porównaniu do zysku z roku 2023, który wynosił $293.51M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Hualan Biological Engineering Inc. od 2001 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $155.12M | -7.51% |
| 2025 | $167.71M | -8.55% |
| 2024 | $183.39M | -37.52% |
| 2023 | $293.51M | 41.74% |
| 2022 | $207.07M | -22.04% |
| 2021 | $265.62M | -19.19% |
| 2020 | $328.71M | 42.15% |
| 2019 | $231.25M | 14.45% |
| 2018 | $202.06M | 42.35% |
| 2017 | $141.94M | 8.99% |
| 2016 | $130.23M | 22.12% |
| 2015 | $106.65M | 5.21% |
| 2014 | $101.36M | 9.59% |
| 2013 | $92.49M | 54.63% |
| 2012 | $59.81M | -18.03% |
| 2011 | $72.97M | -41.17% |
| 2010 | $124.03M | 8.15% |
| 2009 | $114.69M | 259.64% |
| 2008 | $31.89M | 81.62% |
| 2007 | $17.56M | 50.98% |
| 2006 | $11.63M | 57.73% |
| 2005 | $7.37M | 35.90% |
| 2004 | $5.43M | 7.53% |
| 2003 | $5.05M | 23.80% |
| 2002 | $4.08M | 86.85% |
| 2001 | $2.18M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | 3,300.51% |
US
|
|
| $-3.09B | -2,090.06% |
US
|
|
| $-4.02B | -2,689.08% |
AU
|
|
| $3.01B | 1,837.66% |
BE
|
|
| $1.95B | 1,157.50% |
NL
|
